Farhad Kadkhodaei Elyaderani, MD
Clinical Neurophysiology · Bronx, NYNPI 1396972725
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $109,580 of the $156,460 with a category attached, or 70.0%. AbbVie accounts for 62.4% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2024 at $43,755 and has fallen 52.7% since, to $20,705 in 2025. Among clinical neurophysiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,319 payments — averaging $67.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$98K
- Pfizer$22K
- Scilex Pharmaceuticals Inc.$6K
- AstraZeneca$3K
- Teva Pharmaceuticals USA, Inc.$3K
- SK Life Science, Inc.$2K
- plus $23K from 54 others
What the payments were for
- Consulting fees$1,5251%
- Speaking & faculty fees$109,58070%
- Travel & lodging$5950%
- Food & beverage$44,60429%
- Education$1550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$156,460 in reported general payments places this provider in the 95th percentile of 35 clinical neurophysiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 481 | $723,100 |
| QuliptaAtogepant | 453 | $476,750 |
| Nurtec OdtRimegepant Sulfate | 170 | $288,422 |
| ZtlidoLidocaine | 267 | $264,679 |
| GocovriAmantadine Hcl | 128 | $229,178 |
| VraylarCariprazine Hcl | 123 | $168,615 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 15 | $114,215 |
| Aimovig AutoinjectorErenumab-Aooe | 126 | $91,133 |
| ElyxybCelecoxib | 105 | $88,357 |
| Emgality PenGalcanezumab-Gnlm | 130 | $86,375 |
| Doxepin Hcl | 98 | $75,800 |
| BotoxOnabotulinumtoxina | 63 | $75,600 |
| NuplazidPimavanserin Tartrate | 14 | $70,908 |
| ZavzpretZavegepant Hcl | 61 | $63,148 |
| Budesonide ErBudesonide | 69 | $62,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Vraylar, Botox | $97,618 | $1,444,0651,120 claims |
| Scilex Pharmaceuticals Inc.Ztlido, Elyxyb | $6,245 | $353,036372 claims |
| PfizerNurtec Odt, Zavzpret | $22,298 | $351,570231 claims |
| MDD US Operations, LLCGocovri | $2,029 | $229,178128 claims |
| Acadia Pharmaceuticals IncNuplazid | $477 | $70,90814 claims |
| SK Life Science, Inc.Xcopri | $2,305 | $25,40212 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,280 | $24,26216 claims |
| Amneal Pharmaceuticals LLCRytary | $1,339 | $11,70925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 clinical neurophysiology providers in New York.
Other clinical neurophysiology in Bronx
- Jonathan GurskyBronx$1K
- Jillian RosengardBronx$1K
- Swetha PedavallyBronx$778
- Orly WillsBronx$258
- Alcibiades RodriguezNew York$714K
- Jessica Robinson-PappNew York$28K
- Mohini GurmeWest Nyack$13K
- Cecily AntoHauppauge$11K
- Itzhak HaimovicGreat Neck$7K
- Madeline FieldsNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.